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SERUM DECREASES THE SIZE OF METAFECTENE- AND
GENEJAMMER-DNA COMPLEXES BUT DOES NOT AFFECT
SIGNIFICANTLY THEIR TRANSFECTION ACTIVITY IN SCCVII
MURINE SQUAMOUS CELL CARCINOMA CELLS
KRYSTYNA KONOPKA*, NATHAN OVERLID, ANITHA C. NAGARAJ
and NEJAT DÜZGÜNEŞ
Department of Microbiology, University of the Pacific, Arthur A. Dugoni
School of Dentistry, 2155 Webster Street, San Francisco, CA 94115, USA
Abstract: Cationic liposome-DNA (lipoplexes) or polymer-DNA (polyplexes)
complexes have been used to deliver therapeutic genes, both in vitro and in vivo.
However, gene transfer by these non-viral vectors is usually inhibited by
biological milieu. A relatively high efficiency of transfection could be achieved
in human oral cancer cells transfected with the polycationic liposome,
Metafectene, and the polyamine reagent, GeneJammer, in the presence of 60%
fetal bovine serum (FBS) (Konopka et al., Cell. Mol. Biol. Lett. 10 (2005) 455470). Here, we examined the efficacy of these vectors to deliver β−galactosidase
(β-gal), luciferase and Herpes Simplex Virus thymidine kinase (HSV-tk) genes
to SCCVII murine squamous cell carcinoma cells, which are used to generate an
orthotopic murine model of oral cancer. We also evaluated the hydrodynamic
size and zeta potential of the vectors and the effect of FBS and mouse serum (up
to 60%) on the size of Metafectene and GeneJammer complexes with the
pCMV.Luc plasmid. Our results indicate that Metafectene and GeneJammer are
highly effective in transfecting SCCVII cells. Approximately 60-70% of
SCCVII cells transfected with pCMV.lacZ were positive for β-gal staining. The
expression of β-galactosidase was essentially not affected by serum. Mouse
* Corresponding author, e-mail: kkonopka@pacific.edu
Abbreviations used: β-Gal - β−galactosidase; DMEM - Dulbecco’s modified Eagle’s
MEM medium; FBS - fetal bovine serum; GCV - ganciclovir; HBS - HEPES-buffered
saline; HNSCC - head and neck squamous cell carcinoma; HSV-tk - Herpes Simplex Virus
thymidine kinase gene; OSCC - oral squamous cell carcinoma; RLU - relative light units
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serum (20-60%) reduced both Metafectene- and GeneJammer-mediated
luciferase expression by ~30-45%, while FBS did not affect transfection
efficiency. The delivery of the HSV-tk gene by Metafectene or GeneJammer in
the presence of 0% or 60% FBS, followed by GCV treatment for 6 days, resulted
in over 90% cytotoxicity. The mean diameters of the DNA complexes of
Metafectene and GeneJammer decreased significantly as a function of the serum
concentration. The reduction in the size of the lipoplexes and polyplexes by
serum was essentially not inhibitory to transfection of SCCVII cells. This is in
contrast to previous hypotheses that serum-induced decrease in the size of
lipoplexes is the primary cause of serum inhibition of transfection.
Key words: Transfection, Metafectene, GeneJammer, Serum inhibition, HSV-tk
gene, SCCVII murine squamous cell carcinoma cells
INTRODUCTION
Head and neck squamous cell carcinoma (HNSCC) afflicts about 50,000 new
patients each year in the U.S. and more than 500,000 worldwide [1, 2]. Fifty two
% of positively diagnosed patients have a mean survival time of only five years
[3], a statistic that has not changed considerably over the past 20 years. Patients
who survive a first cancer of the oral cavity have a 20-fold increased risk of
developing a second primary oral cancer [4]. About 67% of patients dying of
oral cancer have no evidence of symptomatic distant metastases; thus control of
the localized or regional disease via effective therapies is of utmost importance.
Despite advances in surgery, chemotherapy and radiation of HNSCC, no major
improvement in efficacy and survival has occurred. The treatments cause many
side effects, including jaw pain, mouth sores, dysfunctional salivary glands,
difficulties in chewing, swallowing and talking [5].
Gene therapy approaches may be able to target cancer cells while sparing normal
cells, and may be useful in the treatment of recurrent disease [6-8]. Oral cancer
is a particularly appropriate target for gene therapy, since direct injection of most
primary and recurrent lesions is possible with this approach. Gene delivery
systems include viruses and non-viral vectors. Although generally efficient in
transducing cells, viral vectors suffer from problems of immunogenicity,
toxicity, limits in the size of exogenous DNA, and the risk of inducing
tumorigenic mutations and generating active viral particles through
recombination [8, 9].
Synthetic cationic liposome-DNA (lipoplexes) or polymer-DNA complexes
(polyplexes) provide a simple means of transferring DNA into target cells
[9-11]. Cationic liposomes have been utilized in numerous studies of gene
delivery in vivo [12-17]. It is thought that DNA delivered into the cytoplasm via
lipoplexes is transported inefficiently through the nuclear membrane [18, 19].
The breakdown of the nuclear membrane during mitosis appears to be crucial to
efficient entry of the transfected DNA into the nucleus [20]. Therefore, cell
proliferation may be an important factor in the efficiency of gene transfer, and
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rapidly dividing, transformed cells in HNSCC are likely to be more susceptible
to transgene expression via non-viral vectors compared to normal, non-dividing
cells.
We have focused on establishing a highly efficient and tumor-specific non-viral
gene delivery system for the treatment of oral SCC tumors in immunocompetent
C3H/HeJ mice. This syngeneic orthotopic murine model for HNSCC, that
involves the injection of SCCVII murine squamous cell carcinoma cells in the
floor of the mouth, was developed by O'Malley et al. [21, 22] and has been used
previously in evaluating the efficacy of immunomodulator genes delivered by
adenoviral vectors [23, 24]. The delivery of the murine interleukin-2 (IL-2) gene
via cationic liposomes in combination with the murine IL-12 gene via
a polymeric vector also resulted in significant antitumor effects compared to the
individual cytokine gene treatments and no treatment [25].
As a primer to investigating the use of non-viral vectors in an animal model of
HNSCC, we examined the effect of high concentrations (20-60%) of fetal
bovine serum (FBS) and mouse serum on the delivery of luciferase,
β-galactosidase and Herpes Simplex Virus thymidine kinase (HSV-tk) genes to
SCCVII cells, by the polycationic liposome, Metafectene, and the polyamine
reagent, GeneJammer. We also evaluated the physicochemical properties of
Metafectene and GeneJammer complexes with DNA in terms of their size and
zeta potential. We determined the effect of serum on the size of Metafectene and
GeneJammer complexes with the pCMV.Luc plasmid. We then examined
whether the HSV-tk gene delivered in the presence of high concentrations (up to
60%) of serum, could induce cell death following treatment with GCV. Some of
our results have been presented earlier in preliminary form [26].
MATERIALS AND METHODS
Materials
MetafecteneTM, a polycationic liposomal transfection reagent, containing
a polyamine-lipid and dioleoyl phosphatidylethanolamine (DOPE), was
purchased from Biontex Laboratories GmbH (Munich, Germany). GeneJammer
transfection reagent, a proprietary formulation of polyamine and other
components in 80% ethanol, was obtained from Stratagene (La Jolla, CA).
Alamar Blue dye (alamarBlueTM) was purchased from Biosource International,
Inc. (Camarillo, CA). The β-Gal Staining Kit was obtained from Invitrogen (San
Diego, CA). The penicillin, streptomycin and L-glutamine solutions were
obtained from Irvine Scientific (Santa Ana, CA). Ganciclovir (GCV) was a gift
from Hoffmann-La Roche, Inc. (Nutley, NJ).
Plasmids
The plasmids, pCMV.Luc (VR-1216; a gift of Dr. P. Felgner (Vical, San Diego,
CA)) encoding luciferase, and pCMV.lacZ (Clontech, Palo Alto, CA) encoding
β-galactosidase, were used for evaluating transfection efficiency. The plasmid
pUMVC1-tk (previously designated pNGVL1-tk) expressing thymidine kinase
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was obtained from the National Gene Vector Core Laboratory at the University
of Michigan (Ann Arbor, MI) and propagated by Aldevron (Fargo, ND)
(endotoxin level: <100 EU per mg).
Physicochemical characterization of Metafectene and GeneJammer
complexes with DNA
Complexes were characterized with respect to their size and zeta potential using
a Coulter N4 Plus Submicron Particle Analyzer and a Coulter DELSA 440
(Coulter Corporation, Miami, FL), respectively. The Coulter N4 Plus uses
a photon correlation spectroscopy-based technique, employing autocorrelation
spectroscopy of scattered laser light to determine its time-dependent fluctuations
resulting from the Brownian motion of particles in suspension. The detection
angle was fixed at 90° with 5 min of calibration and 7 min of run time. The
mean particle size of complexes was determined, both in the absence and the
presence of serum. Complexes of Metafectene and GeneJammer with the
pCMV.Luc plasmid were prepared in DME medium. Metafectene was used at
2 µl:1 µg or 4 µl:1 µg DNA and GeneJammer at 3 µl:0.5 µg or 6 µl:0.5 µg
DNA. Where indicated, increasing concentrations of serum were included in the
medium. To evaluate if the presence of serum affected measurements of the size
distribution obtained by the light-scattering method, the size of control latex
beads was determined in the presence of serum. The size distribution was also
determined for DME medium alone containing 0, 20, 40 and 60% FBS or mouse
serum. Measurements were carried out in duplicate 15 min after preparation of
complexes. The Delsa 440 is a laser-based multiangle particle electrophoresis
analyser that measures the electrophoretic mobility and zeta potential
distribution simultaneously with the hydrodynamic size of particles in
suspension. Complexes of Metafectene and GeneJammer with the pCMV.Luc
plasmid were prepared in HEPES-buffered saline (HBS) (20 mM HEPES pH 7.4
and 100 mM NaCl). Samples of the prepared complexes were placed in the
measuring cell, whose position was adjusted to cover a previously determined
stationary level, and an electronic current of 3.0 mA was applied. Measurements
were recorded and the zeta potential was calculated for each scattering angle
(8.7°, 17.4°, 26.8° and 34.7°); the values represent the mean from the different
angles of two measurements. Measurements were carried out 15 min after
preparation of complexes.
Cell culture and transfection
SCCVII is an aggressive murine squamous cell carcinoma cell line that was
established from the squamous cell carcinoma that developed spontaneously in
C3H/HeJ mice and has been propagated subsequently in vitro [27]. For our
studies, SCCVII cells were kindly provided by Drs. D. Li and B. O’Malley
(University of Pennsylvania, Philadelphia, PA). The cells were cultured in
Dulbecco’s modified Eagle’s MEM (DMEM) (Irvine Scientific) supplemented
with 10% FBS (Sigma, St. Louis, MO), penicillin (100 U/ml), streptomycin
(100 µg/ml) and L-glutamine (4 mM) (DMEM/10). Mouse serum was obtained
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from Equitech-Bio, Inc. (Kerrville, TX). For transfection, between 1.0-1.8 x 105
cells were seeded in 1 ml of DMEM in 48-well culture plates one day before
transfection, and used at approximately 60-80% confluence. Cells were prewashed with serum-free DMEM medium and then covered with 0.4 ml of the
same medium. Complexes were prepared by mixing Metafectene or
GeneJammer with 100 µl of serum-free DMEM medium, followed by the
addition of plasmid DNA. The mixture was incubated for 15 min at room
temperature after the addition of the transfection reagent, and another 15 min
after addition of DNA. Metafectene or GeneJammer complexes with DNA were
added in a volume of 0.1 ml per well, the cells were incubated for 4 h at 37°C,
and then 0.5 ml of serum-containing medium was added. For Metafectene and
GeneJammer, the optimal ratio of transfection reagent to DNA was determined
as described previously [28]. It was not possible to determine a +/- (cationic
component/DNA) charge ratio for these reagents, since the chemical structures,
the concentration of the cationic component and the molecular charges have not
been disclosed by the manufacturers. When transfection was performed in the
presence of serum, FBS or mouse serum was added to the cells to a final
concentration as indicated. In experiments involving high concentrations of
serum during the 4-h transfection, the protocol necessitated the use of 30% FBS
in the subsequent incubation phase.
Transfection efficiency and activity
Transfection efficiency was examined by β-Gal staining as described previously
[29]. Luciferase activity was assayed 48 h after transfection, using the Luciferase
Assay System (Promega, Madison, WI), and a TD-20/20 luminometer (Turner
Designs, Sunnyvale, CA). The data were expressed as relative lights units (RLU)
per ml of cell lysate. These values are designated “transfection activity”. The
protein content of the lysates was measured by the DC Protein Assay reagent
(Bio-Rad, Hercules, CA) using bovine serum albumin Fraction V (Sigma) as the
standard.
Cell viability assay
Cell morphology was evaluated by inverted phase contrast microscopy at 25x
magnification. The number of viable cells used for the experiments was
determined by Trypan Blue exclusion. Cell viability was quantified by
a modified Alamar Blue assay [30, 31]. Cell viability (as a percentage of mocktreated control cells) was calculated according to the formula [(A570 - A600) of
test cells] x 100 / [(A570 - A600) of control cells].
Ganciclovir-mediated cytotoxicity
Cells transfected with the HSV-tk plasmid were incubated in the presence of
GCV (20 µg/ml) for the indicated periods of time. Cell viability was quantified
as described above. After removal of the Alamar Blue/medium mixture, fresh
DMEM/10 medium with GCV was added and cells were incubated further at
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37°C. Mock-transfected cells incubated either in the presence or the absence of
GCV served as controls.
Statistical analysis
The statistical evaluation was performed by the unpaired Student's t-test, using
StatView software (BrainPower, Inc., Calabasas, CA). A probability value (P) of
less than 0.05 was considered significantly different.
RESULTS
The effect of serum on Metafectene- and GeneJammer-mediated gene
transfer to SCCVII cells
For many transfection reagents, the presence of serum can interfere with gene
delivery and transfection efficiency [28, 32-38]. We examined the effects of FBS
or mouse serum on transfection of SCCVII cells by the polycationic liposome,
Metafectene, and the polyamine reagent, GeneJammer. SCCVII cells were
chosen since they are employed in the generation of OSCC tumors in an oral
cancer model in C3H/HeJ mice [21, 22]. The ratios of transfection reagent/DNA
(v/w) were selected based on the manufacturers’ recommendations. Experiments
were performed under the optimal conditions. It was not our intention to
compare Metafectene and GeneJammer under identical conditions. Moreover,
this would have been impossible, given the completely different nature of the
two reagents. Metafectene was used at 2 µl:1 µg or 4 µl:1 µg DNA and
GeneJammer at 3 µl:0.5 µg or 6 µl:0.5 µg DNA with the reporter pCMV.Luc
plasmid. The optimal conditions for SCCVII cells were 2 µl Metafectene:1 µg
DNA per well, and 3 µl GeneJammer:0.5 µg DNA per well (data not shown),
and the subsequent experiments were performed under these conditions. SCCVII
cells were readily transfectable and the expression of luciferase was very high,
both with Metafectene and GeneJammer. The luciferase activity was strongly
dependent on the number of cells seeded before transfection and the cell
confluency at the time of transfection. Both with Metafectene and GeneJammer,
the average value of luciferase activity (RLU/ml) in the absence of serum was
1,13 x 106 ± 0.16 x 106, but in some experiments the values were even higher, in
the range of 4-6 x 106 RLU/ml. The high transfection efficiency was also
confirmed by β-gal staining. When SCCVII cells were transfected with the
pCMV.lacZ plasmid using Metafectene or GeneJammer, approximately 60-70%
of the cells were positive for β-gal staining. The β-galactosidase expression was
essentially not affected by FBS or mouse serum (up to 60%) (data not shown).
The expression of luciferase was also examined as a function of serum
concentration. Mouse serum (20-60%) reduced both Metafectene- and
GeneJammer-mediated luciferase expression by ~30-45%, while FBS did not
affect transfection efficiency. It should be noted that the inhibitory effect of
mouse serum was essentially independent of its final concentration (Tab. 1).
When compared to mock-transfected controls, both Metafectene- and

CELLULAR & MOLECULAR BIOLOGY LETTERS

177

GeneJammer-mediated transfection with pCMV.Luc plasmid did not result in
the reduction of cellular protein (data not shown).
Tab. 1. The effect of fetal bovine serum and mouse serum on luciferase gene expression
by SCCVII murine squamous cell carcinoma cells transfected with Metafectene- or
GeneJammer-complexed pCMV.Luc plasmid.
Serum
FBS
FBS
Mouse
Mouse

Transfection
reagent
Metafectene
GeneJammer
Metafectene
GeneJammer

0
100.0 ± 4.3
100.0 ± 7.6
100.0 ± 15.1
100.0 ± 7.3

% Serum
20
40
x
126.1 ± 4.9 102.2 ± 12.1
118.2 ± 14.5
88.7 ± 6.8
x
41.6 ± 7.8x
30.7 ± 2.4
x
46.9 ± 2.5y
45.9 ± 8.7

60
88.4 ± 12.4
99.1 ± 3.9
30.8 ± 7.0x
35.4 ± 7.0y

The actual values of luciferase activity (RLU/ml) for 0% serum are given in the text.
Values represent means ± S.D. from two separate experiments performed in triplicate,
expressed as percentage of luciferase activity (RLU/ml) obtained in the absence of
serum. Values obtained in the presence of 20, 40 and 60% serum significantly different
from the control: x - (P<0.005); y - (P<0.0005).

The effect of serum on Metafectene- and GeneJammer-mediated delivery of
HSV-tk “suicide gene” to SCCVII cells
We next investigated the effect of serum on the expression of the HSV-tk
"suicide gene" in SCCVII cells. Delivery of HSV-tk to target cells results in
expression of viral thymidine kinase, which selectively phosphorylates GCV.
Monophosphorylated GCV is further phosphorylated by cellular enzymes into an
active triphosphate compound. The end product is incorporated into cellular
DNA causing chain termination and inhibition of DNA replication, thus leading
to a cytotoxic effect and cell death. The delivery of the HSV-tk gene to SCCVII
cells by Metafectene in the absence of serum, followed by GCV treatment for
3 and 6 days, resulted in ~68 and 100% GCV-mediated cytotoxicity,
respectively. When transfection was performed in the presence of 60% FBS,
about 36 and 93% cytotoxicity was determined after 3 and 6 days, respectively
(Fig. 1A). GeneJammer-mediated delivery of the HSV-tk gene to SCCVII cells,
followed by GCV treatment for 3 and 6 days, resulted in ~60% and 100%
cytotoxicity, respectively, both in the absence and in the presence of 60% FBS
(Fig. 1B).
To mimic the effect of physiological, or in vivo, conditions on gene transfer, the
delivery of the HSV-tk gene to SCCVII cells was also performed in the absence
or presence of 60% mouse serum. In the absence of serum, followed by GCV
treatment for 3 and 6 days, Metafectene-mediated transfection resulted in ~60
and ~88% GCV-mediated cytotoxicity, respectively. When transfection was
performed in the presence of 60% mouse serum, about 32 and 76% cytotoxicity
was determined after 3 and 6 days, respectively (Fig. 2A). GeneJammermediated delivery of the HSV-tk gene to SCCVII cells, followed by GCV
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treatment for 3 and 6 days, resulted in ~45% and ~90% cytotoxicity,
respectively, both in the absence and the presence of 60% mouse serum
(Fig. 2B).

SCCVII cells

A 160
3 days
6 days

Alamar Blue assay (% of control)

140

a

120
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x

80
60
40

y
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0

y
MF/0/+G

MF/0/-G MF/60/+G MF/60/-G

B

C/0/+G

C/0/-G

C/60/+G

C/60/-G

SCCVII cells
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3 days
6 days

140

Alamar Blue assay (% of control)

a

y
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x
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y
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GJ/0/+G

GJ/0/-G

GJ/60/+G GJ/60/-G

C/0/+G

C/0/-G

C/60/+G

C/60/-G

Fig. 1. The effect of 60% FBS on the sensitivity to GCV of SCCVII cells transfected
with HSV-tk using Metafectene (MF) (A) or GeneJammer (GJ) (B). The cells were
transfected with 2 µl Metafectene and 1 µg plasmid DNA or with 3 µl GeneJammer and
0.5 µg plasmid DNA. Cell viability was measured by the Alamar Blue assay on days 3
and 6 post-transfection. Results are expressed as a percentage of mock-transfected
controls not treated with GCV (C/0/-G and C/60/-G). Data represent the mean ± S.D.
obtained from triplicate wells, and are representative of two independent experiments.
a - significantly different from the control (P<0.01); x - (P<0.05); y - (P<0.0005).
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Fig. 2. The effect of 60% mouse serum on the sensitivity to GCV of SCCVII cells
transfected with HSV-tk using Metafectene (MF) (A) or GeneJammer (GJ) (B). The cells
were transfected with 2 µl Metafectene and 1 µg plasmid DNA or with 3 µl
GeneJammer and 0.5 µg plasmid DNA. Cell viability was measured by the Alamar Blue
assay on days 3 and 6 post-transfection. Results are expressed as a percentage of mocktransfected controls not treated with GCV (C/0/-G and C/60/-G). Data represent the
mean ± S.D. obtained from triplicate wells, and are representative of two independent
experiments. a - significantly different from the control (P<0.025); x - (P<0.005);
y - (P<0.0005).
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In the experiments performed with FBS, Metafectene and GeneJammer were not
toxic in the absence of GCV. In the presence of GCV some cytotoxicity was
observed in the mock-transfected cells after 6 days (P<0.05 compared to -GCV
controls) (Fig. 1A, B). For SCCVII cells transfected at 0% or 60% mouse serum,
a cytotoxic effect of transfection was observed after 6 days in the cells not
treated with GCV. For Metafectene this effect was higher at 0% serum
(P<0.0005 compared to mock-transfected cells -GCV) than at 60% serum
(P<0.025). GeneJammer-mediated transfection was less toxic (P<0.005 at 0%
and P<0.025 at 60% mouse serum). In these experiments, no obvious
cytotoxicity was observed in control wells (Fig. 2A, B). For each condition the
transfection experiment was performed in triplicate wells and it was repeated at
least two times as indicated in the figure legends. While there was little
variability among the triplicates in a particular experiment, there was noteworthy
variability between different experiments. It is likely that the fast growth rate of
SCCVII cells and their tendency to overgrow the culture wells during the long
incubations (6 days), contribute to this variability. Nevertheless, GCV treatment
resulted in a highly significant increase in toxicity compared to cells not treated
with GCV.
Effect of serum on the size of Metafectene and GeneJammer complexes with
DNA
The zeta potentials and mean diameters of Metafectene and GeneJammer
complexes with pCMV.Luc are shown in Tab. 2. The overall charge of the
complexes was negative. Complexes prepared from GeneJammer exhibited
a surface charge close to neutrality. Surprisingly, a more negative zeta potential
was observed when Metafectene/DNA complexes were prepared with a higher
amount of the cationic reagent (Tab. 2). One possible explanation is that the
increase in Metafectene reagent (from 2 µl:1 µg DNA to 4 µl:1 µg DNA) caused
structural alterations in the lipoplex, which enabled the additional cationic
charge to be neutralized by some of the DNA that was not exposed previously.
The resulting particles, then exposed an equivalent negative charge at the shear
plane of the hydrodynamic particle, as observed by the electrophoretic mobility
measurements. It is interesting to note that particle size did not change
appreciably from one charge ratio to the other (Tab. 2).
For liposomes containing the cationic lipid DC-6-14, cholesterol and DOPE
(1:7.5:7.5 molar ratio), increasing the serum concentration up to 100% results in
a significant decrease both in lipoplex size and lipofection efficiency [37]. We
therefore investigated the effect of serum on the size of complexes of
pCMV.Luc with Metafectene or GeneJammer. We first assessed the potential
contribution of serum itself to size determination. Samples of 160 µl of DME
containing 0, 20, 40 and 60% FBS were diluted in 3 ml water. Under these
conditions, a mean particles size of 8 nm was obtained for DME/60% FBS,
while the particle counts at 20 and 40% FBS were too low to produce size
measurements (data not shown). Subsequently, the mean diameter of control
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latex beads was determined in the absence or the presence of serum to evaluate
the contribution of serum to the size determination of standard particles of
defined and constant size. DME medium with 0, 20, 40 and 60% FBS or mouse
serum in a volume of 160 µl were diluted in 3 ml water before adding the control
beads of 500 nm. As shown in Figure 3, the increase in serum concentration in
the medium resulted in a linear decrease in the measurements obtained for the
control beads. A strong linear correlation was found between the concentration
of FBS (R2=0.998) and the mouse serum (R2=0.956), and the results. At 60%
FBS and mouse serum, the apparent mean diameter of 500 nm control beads was
Tab. 2. The zeta potential and mean diameter of Metafectene and GeneJammer
complexes with DNA
Complexes
Metafectene/DNA (v/w) (2:1)
Metafectene/DNA (v/w) (4:1)
GeneJammer/DNA (v/w) (3:0.5)
GeneJammer/DNA (v/w) (6:0.5)

Zeta potential (mV)
- 23.4 ± 3.9
- 30.7 ± 5.2
- 8.3 ± 1.8
- 3.5 ± 1.4

Mean diameter (nm)
2561 ± 477
2327 ± 685
370 ± 40
571 ± 206

Complexes were prepared as described in Material and Methods. The size distribution of
the complexes was assayed in DME medium in the absence of serum. The zeta potential
of the complexes was measured in HBS. Values represent means ± S.D. and are
representative of two separate experiments performed in duplicate.

Mean Diameter (% of control)

120
100
80
60
40
20
0

0

20

40

60

80

Serum (%)

Fig. 3. Effect of FBS concentration on the size of complexes containing Metafectene
(filled circles) or GaneJammer (filled squares) and the pCMV.Luc plasmid, and on the
mean diameter of control latex beads (open circles). The 100% values the latex beads,
Metafectene lipoplexes, and GeneJammer polyplexes were 501 ± 8, 2561 ± 477, and 370
± 40 nm, respectively. Data represent the mean ± S.D. obtained for two measurements
and are representative of two independent experiments.
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in the range of 281 ± 17 and 289 ± 8 nm, respectively, which reflects a reduction
to ~58 ± 2% of controls in the absence of serum. Thus, the presence of serum
affected the apparent size distribution of the control particles. When
measurements were performed with Metafectene- or GeneJammer-DNA
complexes, the decrease in the mean size of the complexes in the presence of
FBS was considerably larger than that of the control beads (Fig. 3). The mean
sizes of the 2 µl Metafectene:1 µg DNA and 3 µl GeneJammer:0.5 µg DNA
complexes were 2561 ± 477 nm and 370 ± 40, respectively (Tab. 2). At 60%
FBS, the mean diameters of the Metafectene/DNA and GeneJammer/DNA
complexes were 39 ± 2 nm and 38 ± 8 nm, respectively. This reflects a reduction
of 98.5% for Metafectene and 90% for GeneJammer. Although in the absence of
serum the mean size of Metafectene-containing complexes was much larger than
that of GeneJammer, extensive condensation in the presence of 60% FBS
resulted in a similar, small size of complexes. Similar results were obtained with
complexes at different reagent:DNA ratios (Metafectene, 4 µl:1 µg DNA;
GeneJammer, 6 µl:0.5 µg DNA; data not shown). Similar results were also
observed with mouse serum, but the percentage of size reduction was lower than
that with FBS. The starting sizes of the 2 µl Metafectene:1 µg DNA and 3 µl
GeneJammer:0.5 µg DNA complexes were 1308 ± 244 nm and 868 ± 83 nm,
respectively. For these complexes, the percentage of size reduction was ~70%
and ~60%, respectively, independent of the concentration of mouse serum (20,
40 and 60%). The observation that the inhibitory effect of serum for transfection
of SCCVII cells was very limited, if any, especially in the case of FBS, suggests
that the lipoplexes or the polyplexes were not dissociating under these
conditions. If they were to dissociate, the complexes would have lost their ability
to transfect the cells. This argument points to condensation being the cause of
reduced particle size. The decrease in the transfection activity with mouse serum
my indeed be caused by dissociation. It should be pointed out, however, that
under these conditions the transfection efficiency (measured by β-gal
expression) was not affected appreciably.
DISCUSSION
Non-viral gene therapy has been gaining increased interest, because it can
overcome some problems inherent to viral therapies, including immune and
toxic reactions and the potential for viral recombination [8, 9]. Non-viral gene
delivery systems, however, also have several limitations: (i) they can be toxic;
(ii) they have a relatively large particle size; (iii) their transfection efficacy is
usually low and often reduced by serum [28, 32-38] (iv) successful transfection
is strongly cell-type dependent [9-11, 19, 28, 29, 39, 40]. Using two novel
transfection reagents, Metafectene and GeneJammer, we showed previously
a significant level of HSV-tk/GCV-mediated cytotoxicity in HSC-3 human
OSCC cells, in the presence of 60% FBS. In contrast, very low transfection
activity and a much higher inhibitory effect of serum were observed in
a different OSSC cell line, H357 [28]. The reasons for the various
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susceptibilities to transfection displayed by relatively comparable cells derived
from OSCC tumors are basically unknown. The rationale might be quite
complex, including differences in endocytosis, intracellular transport and
transcription activity, and in the experimental conditions (including size and
charge ratio of transfection vectors, cell confluency and time of transfection)
[39-43]. Here, we examined Metafectene- and GeneJammer-mediated
transfection in murine SCCVII cells that are used to generate a model of oral
cancer in C3H/HeJ mice [21, 22].
SCCVII cells were readily transfectable in serum-free medium. This high
transfection activity was not affected by FBS, while it was reduced by ~30-45%
in the presence of mouse serum (up to 60%). The distinct effect of various sera
on transfection efficiency has been reported and it has been suggested that
mouse serum more accurately mimics human serum conditions compared to
FBS [38, 44]. Li et al. [44] reported that the addition of mouse serum to
DOTAP:Chol/DNA or DOTAP:DOPE/DNA lipoplexes, at a ratio 1:2 (v/v),
results in immediate aggregation, followed by disintegration of lipoplexes
associated with DNA release. The disintegration rate is affected by lipid
composition and is dependent on the species origin of the serum. Disintegration
of lipoplexes is a much slower process in either fetal bovine serum or human
serum than in mouse serum [44]. It has been suggested that this might be due to
the differences in the amount of active components responsible for vector
disintegration, although it is not known which serum proteins are the major
components responsible for disintegration. These data might explain the higher
inhibition of transfection efficiency by mouse serum observed in our study. The
removal of low-density lipoproteins from mouse serum does not affect its
interaction with lipoplexes [44]. In contrast, Tandia et al. [45, 46] reported that
interactions between lipoplexes and low- or high-density lipoproteins, isolated
from human plasma, lead to inhibition of the transfection activity. The ability of
lipoproteins to inhibit the transfection efficiency of lipoplexes is well correlated
with their potential to undergo lipid mixing with the cationic lipid bilayer [46].
In addition, the effect of serum on transfection efficacy is cell-type specific [28].
For non-viral vectors to be used successfully in vivo, it is important to establish
the molecular basis for the differences in transfection of different cell types, and
the distinct effects of different sera.
Binding of serum components to lipoplexes or polyplexes in vivo may cause an
increase in particle size and entrapment in capillary beds, poor accessibility to
cells or increased clearance of complexes by the reticuloendothelial system
(RES). In vitro, however, larger lipoplexes may result in a greater cellular
association and uptake than smaller lipoplexes [32, 37, 47]. Almofti et al. [37]
have shown that increasing the serum concentration causes a decrease in
binding, uptake and lipofection efficiency, corresponding to a significant
decrease in lipoplex size, using lipoplexes containing the cationic lipid DC-6-14,
cholesterol and DOPE (1:0.75:7.5 molar ratio), complexed with DNA at
a 1.5/1 (+/-) charge ratio. At 50 and 100% FBS the lipoplex size decreases by
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87.5%. The decrease in the size of DOTAP:DOPE/DNA [47] and
lipopolyamine/DNA [32] complexes observed in the presence of FBS (up to
15%) has been considered as the major determinant of the inhibitory effect of
serum, and the use of larger lipoplexes to overcome the inhibitory effect of
serum has been recommended. Faneca et al. [48] reported that the effect of
serum on the size of DOTAP:Chol/DNA complex is affected both by the charge
ratio and by the inclusion of human serum albumin (HSA) in the lipoplexes. For
plain lipoplexes, incubation with 60% FBS for 30 minutes results in no size
changes at the charge ratio 4/1 (+/-) and in a decrease by 60% for the ratio
2/1 (+/-). For HSA-lipoplexes, however, a decrease by 72% for the ratio 4/1 (+/-)
is observed. The presence of serum (up to 20%) does not affect the size of
DOTAP/DNA complexes at a charge ratio of 4/1 (+/-); but a substantial
aggregation of liposomes alone occurs even in the presence of 3% serum [49]. In
all of these studies control experiments evaluating the effect of serum on the size
of latex particles were not performed.
Regarding the possibility that the inhibitory effect of serum on transfection is
mediated by the serum-induced decrease in lipoplex size [32, 37, 47], we have
found that the average diameters of both the Metafectene and GeneJammer
complexes with DNA decrease drastically in the presence of serum. We
observed a similar decrease in size for DOTAP:DOPE/DNA and
DOTAP:Chol/DNA lipoplexes at a 1:1 (+/-) charge ratio in the presence of 60%
FBS (K. Konopka, N. Overlid, N. Düzgünes, unpublished data). We have
observed, however, that the apparent size of control latex particles also
decreases, but in a linear fashion, indicating that the dynamic light scattering
measurements themselves are affected by the presence of serum.
The Coulter N4 Plus Submicron Particle Analyzer determines the particle size
by measuring the rate of diffusion of particles through a diluent. The rate of
diffusion depends on temperature, viscosity and the refractive index of the
diluent, and the particle size. The increase in the viscosity caused by serum
should slow the intensity of particle fluctuations resulting in a lower diffusion
coefficient, which is inversely related to the particle size according to the
Stokes-Einstein equation. As a consequence, the presence of serum should result
in a larger measured mean size of the control latex particles. Therefore, the
observed reduction of size of the control particles is likely to be a consequence
of the change in the refractive index of the diluent according to the theory. The
increase of the refractive index will magnify the decay constant (Γ) and will
reduce the apparent size of the control particles. An additional factor could be
the binding of serum proteins to the polystyrene particles; but this is expected to
increase the actual size of the particles. The small particles present in serum do
not provide enough scattering for signal to be detected, since a mean particle
size of 8 nm was obtained only for DME/60% FBS, while the particle counts at
20 and 40% FBS were too low to produce size measurements (data not shown).
Clearly, further studies are needed to explain the apparent reduction in size of
the control latex particles.
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The observed effect of serum on the size of lipoplexes may be the result of
a number of factors, including viscosity, refractive index, serum protein binding
and the partial dissociation of the lipoplexes. While the sizes of the lipoplexes
and polyplexes decrease exponentially as a function of the serum concentration,
they retain substantial transfection activity in SCCVII cells. Our previous
observations with Metafectene and GeneJammer using different types of cells
have shown that serum is highly inhibitory in the case of H357 cells and less
inhibitory in HSC-3 cells, both of which were derived from human OSCC cells
[28]. It appears, therefore, that cells have different ways of dealing with
lipoplexes or polyplexes of different size, assuming that the size is a major
determinant of transfection [37, 47]. One interesting observation is that if the
efficiency of transfection is high, as in the case of SCCVII cells, serum is not as
inhibitory as for cells that are difficult to transfect (e.g. H357 cells). The fact that
FBS reduces the complex size to a greater extent than mouse serum while not
being as inhibitory for transfection of SCCVII cells suggest that at least for these
cells the complex size is less important. These observations suggest that the
serum-induced decrease in size may not be the primary cause of the serum
inhibition of transfection by non-viral vectors. Thus, our results do not support
the hypothesis that lipoplex size is the major determinant of in vitro lipofection
efficiency.
Although lipoplexes with a high negative zeta potential may be expected to have
a small mean diameter, conflicting results have been reported. Faneca et al. [43]
have reported that DOTAP:DOPE/DNA complexes at a 1/1 (+/-) charge ratio
exhibit a mean diameter of ~250 nm and a zeta potential of –30 mV. On the
other hand, DC-6-14:Chol:DOPE/DNA complexes prepared at a 0.75/1 (+/-)
charge ratio exhibit a mean diameter of 1350 nm and a zeta potential of –26 mV
[42]. Judging from these data our results are not entirely unexpected. It was not
possible to determine the +/- charge ratio for Metafectene/DNA complexes
because the molecular structure, concentration and molecular charge of
Metafectene have not been disclosed.
Our studies are aimed at establishing an efficient and tumor-specific non-viral
gene delivery system for the treatment of OSCC tumors in immunocompetent
C3H/HeJ mice. This syngeneic orthotopic murine model involving SCCVII cells
has the histological characteristics of squamous cell carcinoma, the most
common tumor in the head and neck region [21, 22]. The anatomical site and the
initial regional aggressiveness of this tumor, with early direct extension into the
neck and later cervical lymph nodes, and pulmonary metastases, resemble the
biological behavior of tumor progression in HNSCC [22].
Viral vectors have been employed to deliver HSV-tk to HNSCC cells, both in
vitro and in vivo. Adenovirus-mediated transfer of the HSV-tk gene into human
laryngeal epidermoid cancer cells, HEp-2, and human hypopharyngeal
carcinoma cells, FaDu, followed by exposure to GCV results in significant cell
killing. Injection of the adenovirus HSV-tk vector (AdHSVtk) into tumors
derived from FaDu and HEp-2 cells in SCID mice, followed by GCV treatment,
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results in a reduction of tumor growth [50, 51]. Similar results were obtained
with an adeno-associated virus HSV-tk vector and four human OSCC cells
(SAS, HSC-2, HSC-3, HSC-4) [52]. The conjugation of AdHSVtk with cationic
liposomes enhances the transduction efficiency both in vitro and in vivo [53].
Tumor regression and improved animal survival have been demonstrated in the
oral cancer model described above using AdHSVtk and systemic GCV
administration [54, 55]. The effect of the HSV-tk/GCV treatment is enhanced by
the delivery of the IL-2 gene [23].
Our results indicate that with the non-viral vectors, Metafectene and
GeneJammer, extensive HSV-tk/GCV-mediated cytotoxicity can be achieved in
SCCVII cells even in the presence of high concentrations of FBS or mouse
serum. We are currently working on the translation of our in vitro results with
SCCVII cells to the immunocompetent murine OSCC model.
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